Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous DC-CIK Cells + Autologous NK Cells
- Development stage
- Preclinical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Autologous DC-CIK Cells + Autologous NK Cells** is an adoptive cell therapy (ACT) combination involving patient-derived dendritic cell-activated cytokine-induced killer (DC-CIK) cells and natural killer (NK) cells, administered sequentially or alternately. DC-CIK cells are heterogeneous effector cells with T-cell and NK-like phenotypes, exhibiting MHC-unrestricted cytotoxicity, high proliferation, and broad-spectrum antitumor effects enhanced by dendritic cells for improved antigen presentation. Autologous NK cells provide innate immune killing of tumor and virus-infected cells without prior sensitization. Primarily investigated in solid tumors like rectal cancer with liver metastases, glioblastoma, and gastric cancer, often combined with chemotherapy (e.g., XELOX), it improves immune function, reduces chemotherapy-induced lymphopenia, enhances quality of life, and achieves responses such as partial response (PR) and no evidence of disease (NED), with minimal side effects.[1][2][3]
- Other names
- Autologous CIK/NK CellsDC-CIK + NK Cells
Beyond the preview
Go deeper on Autologous DC-CIK Cells + Autologous NK Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous DC-CIK Cells + Autologous NK Cells.